Sector revisions Monte Rosa Therapeutics, Inc.

Stocks

Market Closed - Nasdaq 04:00:00 26/08/2026 HKT			5-day change	1st Jan Change
14.56 ^USD	+5.70%		-3.13%	-7.14%

08-24	Monte Rosa Therapeutics Doses First Patient in Phase 2 Prostate Cancer Study	MT
08-24	Monte Rosa Therapeutics Doses First Patient In MODeFIRe-1 Phase 2 Study Of MRT-2359 In Combination With Apalutamide In Patients With AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer	CI

Sector:

Location:

X axis:

Main competitors

Add to a list 0 selected To use this feature you must be a member Log in Sign up	1y. EPS revision	Nbr of analysts
MONTE ROSA THERAPEUTICS, INC.		6
LONZA GROUP AG		23
REVOLUTION MEDICINES, INC.		21
IQVIA HOLDINGS INC.		18
BEONE MEDICINES AG		27
CELLTRION, INC.		23
MEDPACE HOLDINGS, INC.		12
ASCENDIS PHARMA A/S	-	19
EUROFINS SCIENTIFIC SE		14
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.		14
ICON PUBLIC LIMITED COMPANY		16
TEMPUS AI, INC.		14
BIO-TECHNE CORPORATION		11
PHARMARON BEIJING CO., LTD.		11
ABIVAX		6
IONIS PHARMACEUTICALS, INC.		22
PRAXIS PRECISION MEDICINES, INC.		19
APOGEE THERAPEUTICS, INC.		11
KYMERA THERAPEUTICS, INC.		22
PROTAGONIST THERAPEUTICS, INC.		13
Average		16
Weighted average by Cap.		19